局限性前列腺癌根治术与非手术治疗的对比研究
被引量：1
摘要
摘译：作者将1994年11月-2002年1月收治的731例局限性前列腺癌随机分为两组，即手术根治组和非手术组，并进行长期随访至2010年1月。主要观察指标是全因死亡率，次要观察指标是前列腺癌的病死率。
出处
《临床误诊误治》
2013年第1期107-107,共1页
Clinical Misdiagnosis & Mistherapy
同被引文献16
-
1Burger J A,Kipps T J.CXCR4:a key receptor in the crosstalk between tumor cells and their microenvironment[J].Blood,2006,107(5):1761-1767.
-
2Sun J,Zhang D,Bae D H,et al.Metastasis suppressor,NDRG1,mediates its activity through signaling pathways and molecular motors[J].Carcinogenesis,2013,34(9):1943-1954.
-
3Jin R,Liu W,Menezes S,et al.The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of b-catenin through mechanisms involving FRAT1 and PAK4[J].J Cell Sci,2014,127(Pt14):3116-3030.
-
4Raman D,Baugher P J,Thu Y M,et al.Role of chemokines in tumor growth[J].Cancer Lett,2007,256(2):137-165.
-
5Sun X Q,Cheng G C,Hao M G,et al.CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression[J].Cancer Metastasis Rev,2010,29(4):709-722.
-
6Yang D L,Xin M M,Wang J S,et al.Chemokine receptor CXCR4 and its ligand CXCL12 expressions and clinical significance in bladder cancer[J].Genet Mol Res,2015,14(4):17699-17707.
-
7Bae D H,Jansson P J,Huang M L,et al.The role of NDRG1 in the pathology and potential treatment of human cancer[J].J Clin Pathol,2013,66(11):911-917.
-
8Song Y,Oda Y,Hori M,et al.N-myc downstream gene-1/Cap43 may play an important role in malignant progression of prostate cancer,in its close association with E-cadherin[J].Hum Pathol,2010,41(2):214-222.
-
9Lee J Y,Kang D H,Chung D Y,et al.Meta-analysis of the relationship between CXCR4 expression and metastasis in prostate cancer[J].World J Mens Health,2014,32(3):167-175.
-
10Chen Q,Zhong T.The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer:a meta-analysis and literature review[J].Drug Des Devel Ther,2015,9:5115-5122.
二级引证文献3
-
1韦秋业,邹崇祺.CXCL12/CXCR4信号通路对肿瘤的作用及机制的研究进展[J].现代肿瘤医学,2017,25(20):3361-3364. 被引量：3
-
2黄国华,唐贤富,唐超来.miR-430和CXCR7在前列腺癌中的表达[J].中国临床研究,2018,31(4):463-466.
-
3薛炜,邱建新,桑楠,张志明.Oct4蛋白对前列腺癌雄激素剥夺治疗后进展速度的预测价值分析[J].解放军医药杂志,2018,30(7):22-25. 被引量：3
-
1拉帕替尼可用于治疗HER2阳性乳腺癌[J].海南医学,2013,24(1):153-153.
-
2莫祎琳.同步放化疗治疗中晚期宫颈癌的效果及毒副反应分析[J].中国医学创新,2017,14(8):102-105. 被引量：3
-
3局限性前列腺癌：观察等待与根治性前列腺切除结局相似[J].癌症进展,2012,10(5):425-425.
-
4蒋友慧.结直肠癌淋巴结被膜外受累对结直肠癌预后的影响及意义:Meta分析[J].中国普外基础与临床杂志,2016,23(11):1388-1388.
-
5倪田根,关泉林,王娜,高晨,周欣,杨含腾.贝伐单抗联合化疗一线治疗转移性结直肠癌有效性和安全性的系统评价[J].肿瘤,2010,30(3):232-238. 被引量：7
-
6Akash Nanda Ming-Hui Chen Michelle H. Braccioforte.激素治疗对伴冠心病充血性心力衰竭或心肌梗死的前列腺癌患者死亡率的影响[J].中国处方药,2009(10):46-46.
-
7周恒,唐其柱,代佳,袁园,石宏伟.血清半乳糖凝集素-3水平与慢性心力衰竭患者预后关系的Meta分析[J].中华临床医师杂志（电子版）,2013,7(23):212-214. 被引量：4
-
8Kuiper JG,Phipps AI,Neuhouser ML.高水平体力活动将显著改善结直肠癌患者生存期[J].中华结直肠疾病电子杂志,2013,2(6):334-334. 被引量：1
-
9谷俊朝.乳腺外科保乳手术的进展（摘译）[J].国际外科学杂志,2014,41(3):205-206.
-
10他汀类可改善前列腺癌近距放射治疗后的结果[J].基础医学与临床,2006,26(3):326-326.
